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Modern tissue engineering technologies have delivered tools to re-create a cell’s naturally 
occurring niche in vitro and to investigate normal and pathological cell-cell and cell-niche 
interactions. Hydrogels based on biomaterials mimic crucial properties of native extracellular 
matrices, including mechanical support, cell adhesion sites and proteolytic degradability. As 
such, they are applied as 3D cell culture platform to replicate tissue-like architectures observed 
in vivo, allowing physiologically relevant cell behaviours. In this chapter, the latest 
bioengineered 3D approaches used for prostate and breast cancer are reviewed. Furthermore, 
the synthesis and use of gelatin methacryloyl-based hydrogels as in vitro 3D cancer model is 
described. This platform is used to engineer the microenvironments for prostate and breast 
cancer cells to study processes regulating spheroid formation, cell functions and responses to 
new drug candidates. Collectively, these bioengineered 3D approaches provide cell biologists 
with innovative pre-clinical tools that integrate the complexity of the disease seen in patients 
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1. Introduction 
Tissue-engineered constructs permit the physiological relevance of biological tissues by 
integrating extracellular matrix (ECM) components, different cell types, vascularisation, as 
well as molecular and biomechanical cues. These engineered microenvironments harbour the 
complexity, temporal dynamics and signalling milieu required for 3D cell culture platforms, in 
vitro disease models and drug screening (Abbott and Kaplan 2015). Various ECM mimics 
derived from natural and synthetic materials are suitable to produce scaffolds or hydrogels for 
3D cell culture, allowing extracellular signalling stimuli and physiologically relevant cell 
functions (Rijal and Li 2016). Next to cell-matrix interactions, cell-cell communications 
between multiple cell types are equally important, for example the co-culture of cancer cells 
with cancer-associated fibroblasts and immune cells recreates immunocompetent 3D cancer 
models for drug discovery studies (Nyga et al. 2016). 
The microenvironment surrounding a tumour has a crucial role in modulating its invasive and 
metastatic capacity and dissemination throughout the body to different tissues or organs, such 
as blood vessels, lung, bone marrow and bone. The induction of angiogenesis is not only 
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required for the haematogenous dissemination of tumour cells but also for the growth of most 
solid tumours, including prostate and breast tumours (Joyce and Pollard 2009). Matrigel, a 
heterogeneous basement membrane mixture derived from Engelbreth-Holm-Swarm (EHS) 
mouse sarcoma, is still the most widely used in vitro system for studying tumour cell invasion, 
angiogenesis and metastasis (Albini 2016). 
Bioengineered 3D models are sophisticated tools to model prostate and breast vascularisation. 
Prostate or breast cancer cells co-cultured with human umbilical vein endothelial cells 
(HUVECs) and mesenchymal stromal cells within star-shaped polyethylene glycol (starPEG)-
heparin hydrogels mimic processes occurring during tumour angiogenesis. This bioengineered 
tumour angiogenesis microenvironment allows cell responses to chemotherapeutics and 
angiogenesis inhibitors at doses that are more clinically applicable than in traditional 2D 
cultures and their analysis in real time compared to in vivo studies, which mostly measure 
endpoint anti-tumour effects (Bray et al. 2015). Moreover, the controlled modulation of this 
3D cell culture platform, via integration of peptide motifs found in collagen or laminin, can be 
used to investigate the biochemical impact of different ECM components on prostate and breast 
cancer cell morphology, proliferation, invasion and angiogenesis (Taubenberger et al. 2016). 
While this particular tissue-engineered approach has been applied to study prostate and breast 
cancer cells in 3D, other biomaterial-based cell cultures have been performed to study specific 
aspects or components of the tumour microenvironment of both cancer entities, which is 
reviewed in the following sections. 
 
1.1. Prostate cancer 
Matrigel is commonly used as a standard in vitro model for prostate cancer, allowing the culture 
and long-term expansion of non-malignant and malignant prostate epithelial cells (Karthaus et 
al. 2014; Gao et al. 2014). As extensively reviewed elsewhere (Loessner et al. 2014), 
bioengineered platforms are excellent tools to delineate not only the contribution of the stromal 
microenvironment to tumour initiation but also metastatic progression to the bone in particular. 
Our group showed that the 3D co-culture of prostate cancer cells, embedded within PEG-based 
hydrogels, and primary human osteoblasts, seeded onto polycaprolactone-tricalcium phosphate 
scaffolds, mimicked paracrine interactions in vitro. Upon 3D co-culture, genes associated with 
the bone matrix, bone remodelling, bone growth factors, transforming growth factor β pathway, 
skeletal and vasculature development were upregulated in prostate cancer cells, indicative of 
osteomimicry processes seen during bone metastasis (Sieh et al. 2014). 
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Other 3D co-culture approaches include for example prostate cancer cells, derived from 
patient-derived xenografts, and murine osteoblasts within hyaluronan-based hydrogels (Fong 
et al. 2016). A microfluidic chamber coated with a collagen type-I hydrogel recreates the bone 
microenvironment of prostate cancer in vitro. Co-culture of bone metastatic prostate cancer 
cells with human bone marrow-derived stromal cells in this integrative system promoted a 
protrusive phenotype and enzyme activity detected by high-resolution imaging techniques 
(Bischel et al. 2014). A polyacrylamide-based hydrogel served as a scaffolding material to 
produce colloidal crystals that resemble the microstructure of decellularised bone to study 
cancer-related metastasis in immune-compromised mice. Hydrogel scaffolds seeded with 
primary human bone marrow-derived stromal cells were implanted subcutaneously and 
orthotopic prostate tumours generated to establish circulating tumour cells and blood-borne 
metastasis over 2 months. Importantly, this hydrogel scaffold induced the engraftment of 
circulating tumour cells and the serial transplantation into tumour-free murine hosts to uncover 
critical stromal-derived factors. The same hydrogel scaffold was also used to study breast 
cancer-related metastases (Bersani et al. 2014). 
Several high-throughput platforms have been developed and are based on 3D cultures of 
prostate cancer cells grown for example in polydimethylsiloxane microwell arrays (Chambers 
et al. 2014) and multilayered hyaluronic acid-based hydrogels (Engel et al. 2015) to screen cell 
functions and responses to drugs. 
 
1.2.Breast cancer 
In the context of breast cancer, the role of the altered microenvironment in cancer development 
and progression has been correlated with in increased stiffness. In fact, tissue stiffening occurs 
through enhanced ECM remodelling, collagen cross-linking, activities of matrix 
metalloproteinases, level of lysyl oxidase, focal adhesions and integrin signalling. Standard in 
vitro models are based on 3D cultures of non-malignant and malignant breast cancer cells using 
collagen type-I hydrogels or a reconstituted basement membrane (rBM) matrix (Levental et al. 
2009). To control and modulate matrix stiffness independent of ligand density in 3D, 
innovative 3D approaches have been developed, for example interpenetrating networks of an 
alginate and rBM matrix. Alginate is derived from seaweed and cross-linked via divalent 
cations, and the rBM matrix is basically Matrigel, which includes amongst others collagen and 
laminin. These interpenetrating hydrogel networks resemble the physical properties of normal 
and cancerous breast tissues and highlight that stiffness and matrix composition act together to 
promote a malignant phenotype (Chaudhuri et al. 2014). An alginate-based, oxygen-controlled 
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3D tumour model showed that hypoxia-related cell responses and tumour angiogenesis are 
critical regulators of pro-inflammatory signalling events in the tumour microenvironment 
(DelNero et al. 2015). 
Other 3D breast cancer models are based for example on laminin-rich ECM (lrECM) 
hydrogels, which have been widely used for studies of glucose metabolism and oncogenesis 
(Onodera et al. 2014). Chitosan-based matrices in combination with hydroxyapatite, a 
structural bone component, allow the modelling if breast cancer-related bone metastases in 
vitro (Zhu et al. 2015). A 3D platform based on aldimine cross-linked collagen type-I hydrogels 
was developed to screen the therapeutic efficacy of humanised monoclonal antibodies in 
blocking breast cancer cell proliferation and initiating apoptosis. The most potent antibody, 
targeting a major collagen type-I integrin receptor, was further validated in vivo and its target 
antigen clinically. Strikingly, the selected antibody showed no inhibitory capacity in traditional 
2D cell culture conditions or Matrigel, indicating that neither recapitulates the structure of the 
basement membrane nor the collagen-rich interstitial matrix (Dudley et al. 2014). Interestingly, 
a microfluidic platform was used to study integrin-based mechanotransduction and fluid 
stresses in breast cancer cells embedded in collagen type-I hydrogels by simulating the 
interstitial fluid pressure of advanced breast tumours (Polacheck et al. 2014). 
A number of high-throughput platforms are available incorporating 3D cultures of breast 
cancer cells that are maintained for example as 3D microtissues using the hanging drop system 
(Anastasov et al. 2015), within polyethylene glycol dimethacrylate-based hydrogel microwell 
arrays (Singh et al. 2016), micropatterned gelatin methacrylate-based hydrogels (Peela et al. 
2016) and a microfluidic array that produces spheroid-laden alginate droplets (Sabhachandani 
et al. 2016). These platforms are majorly used for studies of cellular behaviour and responses 
to chemotherapeutics and/or radiation treatment. 
The dimensionality impacts the cell mechanical properties of highly metastatic cancer cells, 
thereby altering cell signalling and responses to drug treatment. Using an integrated approach 
combining microrheology, a microfluidic device and computational modelling, differences in 
the intracellular mechanical properties of breast cancer cells grown in 2D and 3D within 
collagen type-I hydrogels were confirmed (Mak et al. 2014). Taken together, these studies 
further highlight that 2D cell-based assays inadequately recapitulate 3D cytoskeletal networks, 
mechanical characteristics, cell functions and responses to therapeutics. The accurate 
recreation of the dimensionality of physiological microenvironments in in vitro 3D cancer 
models is a building block to decipher pathological processes. 
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1.3. Gelatin methacryloyl (GelMA)-based hydrogels as in vitro 3D cancer models 
GelMA represents a semi-synthetic matrix combining the advantageous features of naturally-
derived, e.g. Matrigel, rBM, lrECM and collagen type-I, and synthetic materials, e.g. PEG, 
resulting in a hydrogel system with cell binding and degradable sites represented by the native 
ECM, as well as high stability and tunable mechanical properties. Functionalisation of gelatin 
with methacryloyl groups results in a photocrosslinkable polymerisation reaction. Our group 
was the first to apply this bioengineered approach to grow ovarian cancer spheroids in vitro 
and to deliver ovarian cancer spheroids in vivo (Kaemmerer et al. 2014). We have shown that 
ovarian cancer spheroid formation is a function of hydrogel stiffness, resembling cancer 
spheroids present in the tumour fluid (ascites) within the abdominal cavity of patients with 
ovarian cancer. The implantation of spheroid-containing hydrogels into NOD/SCID mice 
caused local tumour growth and a metastatic spread as observed in patients with advanced 
disease. This semi-synthetic hydrogel system offers an inexpensive, reproducible and tailorable 
matrix for 3D cancer cell cultures to improve our understanding of disease progression on a 
cellular level and to screen new anti-cancer drugs (Kaemmerer et al. 2014). In addition, our 
group used GelMA-based hydrogels for cartilage tissue engineering due to its versatile 
mechanical properties (Levett et al. 2014). 
 
In this book chapter, we report the synthesis of GelMA (section 3.1.), and, for the first time, 
the characterisation of the degree of amine functionalisation of GelMA (section 3.2.), as well 
as the suitability of GelMA-based hydrogels to grow prostate and breast cancer cell spheroids 
over a 3D culture period of 14 days (section 3.3.). These cancer spheroid cultures can then be 
utilised for a number of different bioassays to assess cell viability (section 3.4.), morphology 




2.1.1. GelMA synthesis 
 Gelatin from porcine skin, type A, 300 bloom, Sigma-Aldrich 
 Methacrylic anhydride (MAAh), Sigma-Aldrich (hazardous) 
 Phosphate-buffered saline (PBS), pH 7.4, Life Technologies 
 Demineralised or ultrapure (MilliQ) water 
 NaOH, Sigma-Aldrich 
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2.1.2. Characterisation of GelMA functionalisation 
 2,4,6-Trinitrobenzenesulfonic acid (TNBS), 5% (wt/vol) solution, Sigma-Aldrich 
 NaHCO3, Sigma-Aldrich 
 Demineralised or ultrapure (MilliQ) water 
 
2.1.3. Cell encapsulation and culture 
 70% Ethanol, Life Technologies 
 Irgacure® 2959 (IC2959), BASF 
 PBS (as above) 
 
2.1.3.1. Human prostate cancer LNCaP cell culture 
 LNCaP cells, ATCC CRL-1740 
 RPMI medium 1640, L-glutamine, no phenol red, Life Technologies 
 Fetal bovine serum (FBS), Life Technologies 
 Penicillin-streptomycin, 10,000 U/ml, Life Technologies 
 Trypsin-EDTA, no phenol red, Life Technologies 
 PBS (as above) 
 
2.1.3.2. Human breast cancer MCF-7 cell culture 
 MCF7 cells, ATCC HTB-22 
 Eagle’s minimum essential medium (EMEM), L-glutamine, Life Technologies 
 FBS (as above) 
 Penicillin-streptomycin (as above) 
 Insulin, Sigma-Aldrich 
 Trypsin-EDTA (as above) 
 PBS (as above) 
 
2.1.4. Assessment of cell viability 
 Fluorescein diacetate (FDA), Life Technologies 
 Propidium iodide (PI), Life Technologies 
 Acetone, Life Technologies 
 PBS (as above) 
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2.1.5. Assessment of cell morphology 
 Paraformaldehyde (PFA), Sigma-Aldrich (danger) 
 Triton X-100, Sigma-Aldrich 
 Glycine, Sigma-Aldrich 
 Bovine serum albumin, Sigma-Aldrich 
 E-cadherin antibody, monoclonal (#EP700Y), Life Technologies 
 Alexa488-conjugated goat anti-rabbit antibody, polyclonal, Life Technologies 
 Rhodamine 415-conjugated phalloidin, Life Technologies (hazardous) 
 4´,6-Diamidino-2-phenylindole (DAPI), Life Technologies 
 
2.1.6. Assessment of cell proliferation 
 Quant-iT™ Picogreen® ds DNA assay kit, Life Technologies 
 Proteinase K, Life Technologies 
 Na2HPO4, Merck Chemicals 
 NaH2PO4 × H2O, Merck Chemicals 
 Na2EDTA, Life Technologies 
 Demineralised or ultrapure (MilliQ) water 
 
2.2. Equipment 
2.2.1. GelMA synthesis 
 Round bottom flasks (500 ml volume) 
 Laboratory magnetic stirrer with heating function 
 Large magnetic stirring bar 
 Chemical safety fume hood 
 Temperature-controlled water bath 
 Laboratory balance 
 50 ml falcon tubes 
 Laboratory glassware 
 Laboratory benchtop centrifuge 
 Dialysis membrane, 12 kDa molecular weight cut-off, Sigma-Aldrich 
 Sterile syringes (50 ml volume) 
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 Nalgene™ Rapid-Flow™ sterile disposable filters with polyethersulfone (PES), 0.2 µm 
pore size, Life Technologies 
 Lyophiliser (freeze-dryer) 
 
2.2.2. Characterisation of GelMA functionalisation 
 Temperature-controlled water bath 
 15 ml falcon tubes 
 Clear 96-well plates 
 Laboratory shaker/rocker plate 
 Laboratory oven 
 Microplate photometer 
 
2.2.3. Cell encapsulation and culture 
 Cell culture incubator 
 Sterile cell culture flasks (75 cm2) 
 Biological safety cabinet 
 Analytical balance 
 Temperature-controlled water bath 
 Laboratory benchtop centrifuge 
 Teflon hydrogel casting mould, custom-made with circular recesses (⌀ = 5 mm, h = 2 
mm); alternative design reported previously (Loessner et al. 2016) 
 Microscope glass slides, ProSciTech 
 Spatula 
 Forceps 
 CL-1000 ultraviolet (UV) crosslinker with 365 nm wavelength tubes, UVP 
 24-well plates, cell culture-treated 
 Haemocytometer or cell counter 
 50 ml falcon tubes 
 
2.2.4. Assessment of cell viability 
 Spatula 
 24-well plates, cell culture-treated 
 Microscope glass slides (as above) 
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 Standard fluorescence or confocal laser scanning microscope (CLSM), with FITC and 
TRITC filter sets 
 
2.2.5. Assessment of cell morphology 
 Spatula 
 24-well plates, cell culture-treated 
 0.2 μm syringe filter units 
 CLSM 
 
2.2.6. Assessment of cell proliferation 
 Spatula 
 2 ml centrifuge tubes 
 Heating block 
 Laboratory benchtop centrifuge 
 Black 96-well plates 
 Laboratory shaker/rocker plate 
 Fluorescence microplate reader 
 
2.3. Reagent setup 
2.3.1. GelMA synthesis 
Prepare 5 M NaOH solution by dissolving 20 g of NaOH in 80 ml of demineralised or ultrapure 
(MilliQ) water and adjust to a final volume of 100 ml. 
 
2.3.2. Characterisation of GelMA functionalisation 
Prepare 0.1 M NaHCO3 buffer by dissolving 8.4 g of NaHCO3 in 1 liter of demineralised or 
ultrapure (MilliQ) water and adjust the pH to 8.5. Prepare 0.01% (wt/vol) TNBS solution by 
diluting TNBS stock solution in demineralised or ultrapure (MilliQ) water in a chemical safety 
fume hood (1:500 dilution). 
 
2.3.3. Cell encapsulation and culture 
Prepare photoinitiator solution by dissolving IC2959 at 0.05% (wt/vol) in PBS by heating to 
70 °C in a water bath protected from light for 10-15 min or until fully dissolved. 
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2.3.3.1. Medium for LNCaP cell culture 
Supplement RPMI with 5% (vol/vol) FBS and 100 U/ml penicillin-streptomycin. Medium can 
be stored at 4 °C for 4-6 weeks. 
 
2.3.3.2. Medium for MCF-7 cell culture 
Supplement EMEM with 10% (vol/vol) FBS, 100 U/ml penicillin-streptomycin and 
0.01 mg/ml insulin. Medium can be stored at 4 °C for 4-6 weeks. 
 
2.3.4. Assessment of cell viability 
Prepare a 10 mg/ml stock solution of FDA in PBS by dissolving 100 mg of FDA in 10 ml of 
acetone and store protected from light at -20 °C for up to 1 year. Freshly prepare the required 
volume of the FDA/PI staining solution (1 ml per sample) by adding 1 μl of each stock solution 
to 998 μl of PBS to obtain a final FDA and PI concentration of 10 μg/ml and 5 μg/ml 
respectively. 
 
2.3.5. Assessment of cell morphology 
Prepare a 4% (wt/vol) solution of PFA dissolved in PBS according to your laboratory’s 
standard procedures and store at -20 °C for up to 1 year. Prepare a 0.2% (vol/vol) triton X-100 
solution by adding 20 µl triton X-100 to 10 ml of 4% (wt/vol) PFA solution while stirring and 
store at 4 °C up to 2 months (alternatively, prepare a 0.2% (vol/vol) triton X-100 solution by 
adding 20 µl triton X-100 to 10 ml of PBS). Prepare a 0.1 M glycine solution by dissolving 
377 mg of glycine in 50 ml of PBS and store at 4 °C for up to 2 months. Prepare a 1% (wt/vol) 
solution of BSA by dissolving 1 g of BSA in 100 ml of PBS and store at 4 °C up to 2 months. 
Prepare a 5 mg/ml stock solution of DAPI by dissolving 10 mg of DAPI in 2 ml of PBS and 
store protected from light at -20 °C for up to 1 year. It is recommended that the following 
solutions are filter-sterilised using 0.2 μm syringe filter units before usage: 4% (wt/vol) PFA, 
glycine 0.1 M and 1% (wt/vol) BSA solutions. Prepare the following staining solutions 
immediately before usage: 1:400 dilution of E-cadherin antibody in 1% (wt/vol) BSA solution, 
1:1,000 dilution of Alexa488-conjugated anti-rabbit antibody in 1% (wt/vol) BSA solution, 
0.3 U/ml rhodamine 415-conjugated phalloidin in 1% (wt/vol) BSA solution and 2.5 µg/ml 
DAPI in PBS. 
 
2.3.6. Assessment of cell proliferation 
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Prepare phosphate-buffered EDTA (PBE) buffer containing 20 mM Na2HPO4, 30 mM 
NaH2PO4 × H2O and 5 mM Na2EDTA in 500 ml of demineralised or ultrapure (MilliQ) water, 
adjust to pH 7.1 and autoclave at 121 °C for 15 min. Prepare a 100 mg stock solution of 
proteinase K in 10 ml of PBE buffer and store at 4 °C up to 1 year. Prepare a fresh solution of 
0.5 mg/ml proteinase K in PBE buffer for each experiment. Prepare a fresh PicoGreen dye 
solution following the manufacturer’s instructions. 
 
3. Methods 
The step-by-step protocol for the preparation of the GelMA polymer, used to prepare hydrogel-
based 3D cell culture models for cancer and stem cell research, as well as for tissue engineering 
applications, has been reported previously (Loessner et al. 2016). Our group developed quality 
control and validation procedures, for example to assess the degree of GelMA functionalisation 
and mechanical properties, to ensure reproducibility in in vitro and in vivo studies, with 
particular focus on ovarian cancer, cartilage tissue engineering, bone colonisation and vascular 
networks (Loessner et al. 2016). The methods described in this chapter report, for the first time, 
a step-by-step protocol for spheroid cultures for widely used prostate and breast cancer cells to 
establish in vitro 3D cancer models. In particular, the production of the GelMA polymer 
(Figure 1A), the encapsulation and culture of LNCaP and MCF-7 cells in 4% (wt/vol) GelMA-
based hydrogels (Figure 1B), as well as bioassays used to assess cell viability, morphology and 
proliferation are described (Figure 1C). 
 
3.1. GelMA synthesis 
Gelatin can be functionalised with photocrosslinkable methacryloyl groups by reaction with 
methacrylic anhydride (MAAh) to result in GelMA (Figure 1A). MAAh is hazardous and nust 
be handled with care. Suitable personal protective equipment is required, and the synthesis 
reaction, including all steps involving unsealed MAAh, must be performed in a chemical safety 
fume hood. Maintain gelatin and GelMA solutions at 40 °C between all steps to avoid thermal 
gelation (reversible), unless specified otherwise. 
 
 Weigh 10-30 g of gelatin into a 500 ml round bottom flask and add PBS to a final 
gelatin concentration of 10% (wt/vol). Add a magnetic stirring bar and place the round 
bottom flask into a water bath on a laboratory magnetic stirrer heated to 50 °C inside a 
chemical safety fume hood (Figure 2A-B). 
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 Dissolve gelatin by moderately stirring for approximately 2 hrs or until the solution 
appears clear and homogeneous (Figure 2C). 
 Meanwhile, transfer a laboratory balance into the chemical safety fume hood. Weigh 
0.6 g of MAAh per gram of gelatin into a clean glass beaker using a glass pipette. 
 Increase the stirring speed as much as possible and carefully add MAAh. Continue 
stirring for 3 hrs at 50 °C to facilitate the functionalisation of gelatin with 
photocrosslinkable methacryloyl groups (Figure 2D). Note 4.1. 
 Aliquot the reaction mixture into 50 ml falcon tubes. 
 Pre-heat about 500 ml of demineralised or ultrapure (MilliQ) water in a glass bottle 
using a water bath heated to 40 °C for about 15 min. 
 While the water is pre-heating, transfer the 50 mL falcon tubes containing the GelMA 
solution into a laboratory benchtop centrifuge and pellet unreacted MAAh by 
centrifugation at 3,500 g for 3 min. Transfer the 50 mL falcon tubes into a chemical 
safety fume hood and decant the supernatant containing GelMA into a clean glass 
beaker. Discard the pellet. Add approximately one volume of pre-heated demineralised 
or ultrapure (MilliQ) water to the GelMA solution (Figure 2E). 
 To remove by-products and salts, transfer the diluted GelMA solution into dialysis 
membrane (12 kDa molecular weight cut-off; Figure 2F) and dialyse at 40 °C against 
demineralised or ultrapure (MilliQ) water for 5-7 days protected from light. Change the 
water at least once daily. Dialysis is completed when the solution appears clear, and the 
odour of MAAh is no longer noticeable (Figure 2G). 
 Transfer the GelMA solution into a clean glass beaker and adjust the pH to 7.4 using 
5 M NaOH (see Reagent setup). 
 Transfer the neutralised GelMA solution into a biological safety cabinet, and sterile-
filter using 0.2 μm syringe filter units with a polyethersulfone (PES) membrane (most 
other membrane types will clog) into sterile 50 ml falcon tubes. Freeze overnight at -
80 °C. 
 Transfer frozen aliquots to a lyophiliser and freeze-dry for 5 days (screw caps need to 
be loosened slightly to allow gas exchange) or until GelMA is fully dehydrated. Store 
at -20 °C until usage (Figure 1A). 
 
3.2. Characterisation of GelMA functionalisation 
14 
It is recommended to characterise the degree of functionalisation (DoF) of every newly 
synthesised GelMA batch to ensure reproducibility between batches. While both primary 
amines and hydroxyl-groups of gelatin react with MAAh to form methacrylamides and 
methacrylates respectively, over 90% of the functionalisation occurs at primary amines (Yue 
et al. 2015). As a viable alternative to 1H-NMR analysis, the method outlined in this chapter 
assesses the degree of amine functionalisation (DoAF) in GelMA as an approximation of the 
total DoF. 
 
 Prepare 0.1 M NaHCO3 buffer and 0.01% (wt/vol) TNBS solution (see Reagent setup). 
 Weigh 100 mg of GelMA and unfunctionalised gelatin into two separate 15 ml falcon 
tubes. Add 0.1 M NaHCO3 buffer to a concentration of 10 mg/ml respectively and 
dissolve by heating to 37 °C in a water bath for approximately 1 hr, mixing occasionally 
until solutions appear clear and homogenous. Transfer 250 μl of each solution to a new 
15 ml falcon tube and dilute with 4.75 ml 0.1 M NaHCO3 buffer to obtain GelMA and 
gelatin concentrations of 500 μg/ml respectively. Note 4.2. 
 Prepare 1:2 dilution series of GelMA and gelatin solutions: 500 μg/ml, 250 μg/ml, 
125 μg/ml, 62.5 μg/ml, 31.25 μg/ml and 0 μg/ml, with at least 600 μl final volume per 
dilution. 
 For triplicate measurements, transfer three times 200 μl of each GelMA and gelatin 
dilution into a clear 96-well plate. Add 100 μl of 0.01% (wt/vol) TNBS solution to each 
well and mix on a shaker/rocker plate for 5 min protected from light. 
 Incubate at 37 °C in a laboratory oven for 2 hrs protected from light. 
 Measure the absorbance at 335 nm using a microplate photometer. 
 Subtract the mean absorbance of the blanks (0 μg/ml) from each value. Calculate the 
mean absorbance of triplicate measurements and plot linear regression lines for each 
GelMA and gelatin and ensure R2 ≥ 0.95. Determine the slope of both regression lines 





3.3. Cell encapsulation 
The method described herein focuses on the encapsulation of LNCaP or MCF-7 cells in 4% 
(wt/vol) GelMA-based hydrogels for application as in vitro 3D cancer models (Figure 1B). The 
handling of cells is performed in a biological safety cabinet using only sterile equipment and 
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reagents. Before commencing this procedure, expand LNCaP and MCF-7 cells in tissue culture 
flasks to approximately 70-80% confluency. 
 
 Sterilise the Teflon casting mould, microscope glass slides and spatula by spraying with 
70% (wt/vol) ethanol, followed by air-drying. 
 Prepare 0.05% (wt/vol) photoinitiator solution (see Reagent setup). 
 To weigh in GelMA without compromising sterility, determine the weight of a sterile 
50 ml falcon tube and add GelMA in a biological safety cabinet using sterile forceps. 
Weigh the tube again and determine the amount of GelMA by subtracting the weight 
of the empty 50 ml falcon tube. 
 Add photoinitiator solution to a final GelMA concentration of 4% (wt/vol). Dissolve 
this GelMA precursor solution in a water bath heated to 37 °C for approximately 3 hrs 
or until solution appears clear and homogenous. 
 Once GelMA is fully dissolved, detach LNCaP or MCF-7 cells using trypsin-EDTA 
according to your laboratory’s standard procedures, and wash the cell pellet with 20 ml 
of PBS to remove traces of trypsin. Centrifuge again and discard the supernatant. 
Resuspend the cell pellet in the respective culture medium (see Reagent setup) and 
determine the cell number using a haemocytometer or cell counter. 
 Calculate the required number of cells (ncells) based on the volume of GelMA precursor 
solution (VGelMA) and the desired cell density (here: 3.5 × 10
5 cells/ml GelMA precursor 
solution) using the equation ncells = VGelMA × 3.5 × 10
5 cells/ml. Pellet the required 
amount of cells by centrifugation, remove the supernatant, and add the GelMA 
precursor solution to a the cell density of 3.5 × 105 cells/ml. Mix carefully by pipetting 
up and down to yield a single cell suspension while avoiding introduction of air bubbles. 
Note 4.3. 
 Transfer the cell-containing hydrogel precursor solution into the resesses of the sterile 
casting mould and cover with a sterile glass slide. Avoid the introduction of air bubbles. 
Note 4.4. 
 Photocrosslink the cell-containing hydrogel precursor solution by exposure to 365 nm 
at 2.5 mW/cm2 UV light for 12 min. Note that exposure times may vary depending on 
the intensity of the 365 nm light source and the design of the casting mould. Optimise 
exposure times to yield hydrogels with a Young’s modulus of approximately 5 kPa. 
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 Culture cell-laden hydrogel constructs in suitable culture medium (see Reagent setup) 
using 24-well plates at 37 °C and 5% CO2 (Figure 1B). 
 
3.4. Assessment of cell viability 
Living and dead cells encapsulated in GelMA-based hydrogels can be visualised with a 
fluorescence microscope using a FDA/PI staining. It is recommended to assess cell viability 
one day after cell encapsulation and at any other desired time point. This procedure represents 
an endpoint analysis and cell-laden hydrogels may be discarded or employed for 
immunostaining (see 3.5.) afterwards. 
 
 Prepare FDA/PA staining solution (see Reagent setup). 
 Carefully remove cell-laden hydrogels from culture medium using a sterile spatula and 
wash in 1 ml PBS for 10 min at room temperature (RT) in a 24-well plate. Discard 
culture medium. 
 Incubate in 1 ml FDA/PI staining solution for 10 min at RT. 
 Wash in 1 ml PBS for 5 min at RT. 
 Remove from PBS and place cell-laden hydrogel on a microscope glass slide. 
 Immediately capture images of living (fluorescein excitation/emission maxima: 
490/525 nm) and dead (PI excitation/emission maxima: 493/636 nm) cells using a 
standard fluorescence microscope or CLSM at 4-20x magnification as desired. 
 
3.5. Assessment of cell morphology 
To visualise the morphology of hydrogel-encapsulated cells and spheroids, (immuno-) 
fluorescent staining of an epithelial cell marker (here: E-cadherin) as well as the cytoskeleton 
and cell nuclei can be used and imaged by CLSM. 
 
 Prepare 4% (wt/vol) PFA, 0.2% (vol/vol) triton X-100, 0.1 M glycine and E-cadherin 
antibody solutions (see Reagent setup). 
 Remove cell-laden hydrogels from culture medium using a sterile spatula and wash in 
1 ml PBS for 10 min at RT. Discard culture medium. 
 Fix and permeabilise samples with 1 ml 4% (wt/vol) PFA containing 0.2% (vol/vol) 
triton X-100 in a 24-well plate on a shaker/rocker plate for 30 min at RT. Note 4.5. 
 Wash with 1 ml 0.1 M glycine solution, then twice with 1 ml PBS for 5 min each at RT. 
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 Incubate in E-cadherin antibody solution overnight at 4 °C protected from light. 
 Prepare Alexa488-conjugated anti-rabbit antibody, rhodamine 415-conjugated 
phalloidin and DAPI solutions (see Reagent setup). 
 Wash twice with 1 ml of PBS for 5 min each at RT. 
 Incubate in Alexa488-conjugated anti-rabbit antibody solution (see Reagent setup) for 
1 hr at RT protected from light. 
 Incubate in rhodamine 415-conjugated phalloidin solution for 1 hr at RT protected from 
light. 
 Wash twice with 1 ml of PBS for 5 min each at RT. 
 Incubate in DAPI for 40-50 min at RT protected from light. 
 Wash twice with 1 ml of PBS for 5 min each at RT. 
 Using a CLSM, image with a 10/20x oil objective to acquire z-stacks with a slice 
thickness of 2-5 μm (Figure 3C) and generate maximal intensity projections as reported 
previously (Loessner et al. 2016). 
 
3.6. Assessment of cell proliferation 
The total DNA content of cell-laden GelMA-based hydrogels can be assessed using a Quant-
iT™ Picogreen® ds DNA assay kit following sample digestion with proteinase K. The increase 
in DNA content over the culture duration corresponds to an increase in cell number. To 
investigate the proliferation of LNCaP or MCF-7 cells in GelMA-based hydrogels, this method 
can be performed at day 1 and at the endpoint of culture, for example at day 14 (Loessner et al. 
2013). 
 
 Prepare PBE buffer and proteinase K solution (see Reagent setup). 
 At the desired time point, transfer cell-laden hydrogels (triplicate or more per 
experimental condition) to 2 ml centrifuge tubes using a spatula. Note that samples may 
be frozen at -20 °C for later processing or used immediately. 
 Incubate cell-laden hydrogels in 500 µl proteinase K solution overnight at 65 °C in a 
heating block or until fully digested. 
 Prepare DNA standards in PBE buffer with the provided Lambda DNA standard by 
diluting 1:2 over the following concentrations: 2,000 ng/ml, 1,000 ng/ml, 500 ng/ml, 
250 ng/ml, 125 ng/ml, 62.5 ng/ml, 31.25 ng/ml and 0 ng/ml, with at least 300 μl final 
volume per dilution. 
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 Prepare the PicoGreen dye solution (see Reagent setup; for triplicate measurements, 
300 µl per sample and Lambda DNA standard are required). 
 Samples may need to be diluted 1:10, 1:20 or 1:50 in PBE buffer, according to the 
expected DNA content. Note 4.6. 
 For triplicate measurements, transfer three times 100 µl of each (diluted) sample and 
Lambda DNA standard to a black 96-well plate. Note 4.7. 
 Add 100 µl of PicoGreen dye solution to each well and incubate for 5 min at RT 
protected from light on a shaker/rocker plate. 
 Measure fluorescent signals (excitation/emission maxima: 480/520 nm) using a 
fluorescence plate reader. 
 Determine DNA concentrations of the sample digests compared to a linear regression 
line of the Lambda DNA standard. To determine the total DNA content of a sample, 
multiply the obtained DNA concentrations with the dilution factor used and the total 
digest volume (here: 0.5 ml; Figure 3B). 
 
4. Notes 
4.1. Note that the stirring speed may vary depending on the setup and volume used. As a general 
guideline, the solution turns opaque after addition of MAAh (Figure 2D). If visible phase 
separation occurs, increase the stirring speed or use an overhead stirrer. 
 
4.2. Alternatively, GelMA and gelatin may be directly dissolved at 500 μg/ml in NaHCO3 
buffer. However, accuracy may be affected if GelMA and gelatin are dissolved at such low 
concentrations. 
 
4.3. Other GelMA and IC2925 concentrations and cell densities tested were reported previously 
(Loessner et al. 2016). 
 
4.4. Avoid introduction of air bubbles as oxygen may partially inhibit the polymerisation of 
GelMA. 
 
4.5. Fixation and permeabilisation can be carried out in two individual steps. Samples can be 
stored in 4% (wt/vol) PFA in PBS at 4 °C for up to 1 month. When ready to proceed with the 
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fluorescent staining, permeabilise samples in 0.2% (vol/vol) triton X-100 in PBS for 30 min at 
RT. 
 
4.6. It is recommended to optimise the dilution factor using 1-2 samples with the lowest and 
highest expected DNA content respectively, for example from day 1 and day 14. The final 
DNA concentration in the diluted digest should be in the linear range between 0 and 
2,000 ng/ml. 
 
4.7. If more than one black 96-well plate is needed, it is recommended to prepare a Lambda 
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Figure 1: Schematic illustrating GelMA production and application as 3D cancer model. 
(A) GelMA is synthesised by a reaction of gelatin and methacrylic anhydride (MAAh). 
Following dialysis to remove reaction by-products and salts, the solution is lyophilised 
resulting in dry GelMA foam. To control the GelMA quality, thus ensuring high reproducibility 
between batches, the degree of functionalisation is assessed with a 2,4,6-
trinitrobenzenesulfonic acid (TNBS) assay. (B) To prepare cell-laden hydrogels, GelMA is 
dissolved in PBS containing the photoinitiator Irgacure® 2959 (IC2959) and mixed with cells 
(LNCaP or MCF-7). The cell-containing precursor solution is cast into a Teflon mould and 
photocrosslinked to form cell-laden hydrogel constructs (4 mm × 4 mm × 2 mm). (C) Cell-
laden hydrogel constructs are cultured over a certain period of time, for example 14 days, to 
allow spheroid formation for use as in vitro 3D cancer model. The effects of novel drug 
candidates using this 3D cancer model can be investigated through the assessment of cell 
morphology, viability and proliferation. 
 
Figure 2. GelMA functionalisation and dialysis. (A-B) Gelatin is dissolved in PBS in a round 
bottom flask with a magnetic stirring bar placed inside a water bath that is heated to 50 °C. For 
large reaction volumes (up to 1 litre as depicted), an overhead stirrer with propeller agitator is 
recommended. (C) After approximately 2 hrs, the mixture appears clear, indicating that gelatin 
is completely dissolved. (D) While stirring, methacrylic anhydride (MAAh) is added and the 
solution turns opaque. (E) After 3 hrs, the solution is transferred into 50 ml tubes and unreacted 
MAAh is removed by centrifugation at 3,500 g for 3 min; an opaque and viscous pellet is 
visible. (F) The GelMA-containing supernatant is decanted into a glass beaker, diluted with 
demineralised water and transferred into a dialysis membrane. (G) The dialysis is carried out 
at 40 °C against a large volume of demineralised water for 5-7 days in a chemical safety fume 
hood, with daily water changes, until the GelMA solution appears clear. 
 
Figure 3. Application of GelMA-based hydrogels as in vitro 3D cancer model. (A) Prostate 
cancer LNCaP and breast cancer MCF-7 cells are encapsulated within GelMA-based hydrogels 
(4% (wt/vol) polymer concentration). After 1 day, cell viability is assessed by confocal 
microscopy performing a live/dead staining. Fluorescein diacetate stains living cells (green), 
and propidium iodide identifies dead cells (red). Both LNCaP and MCF-7 cells have a cell 
viability of >95%. (B) After 14 days, the DNA content is determined using a Picogreen® ds 
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DNA assay kit (n=3 using triplicate hydrogel samples; mean±SEM). Both LNCaP and MCF-7 
cells have a similar DNA content. (C) After 14 days, cell morphology is assessed by confocal 
microscopy staining the epithelial cell marker E-cadherin (green), the cytoskeleton (red) and 
cell nuclei (blue). 
